Subscribe To

Price Alert Latest News Economic Calendar News

MORF / Morphic to Present at TD Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference. Read More

Demo Live Account See Partner Details

Content Topics

Morphic

Present

Cowen

43rd

Annual

Health

Care

Conference

Stock

MORF

Posted: Mar 3 2023, 09:05

Author Name: GlobeNewsWire

MORF News

By Seeking Alpha
September 28, 2023

Morphic Holding: The Price Drop Is Very Interesting

Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets

By GlobeNewsWire
September 22, 2023

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-

By Zacks Investment Research
August 3, 2023

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares t

By Seeking Alpha
July 10, 2023

Morphic: High Valuation Not Justified By Data, Development Status, Or Cash

Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage compan

By The Motley Fool
April 29, 2023

3 Biotech Buyout Targets to Watch

89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.

By Seeking Alpha
April 25, 2023

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023

Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023.

By Zacks Investment Research
April 25, 2023

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares t

By Zacks Investment Research
April 18, 2023

Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings esti

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.